Method to Activate Fetal Hemoglobin Expression (SJ-20-0020)

St. Jude Reference #SJ-20-0020


Researchers at St. Jude recreated the naturally occurring point mutation in the human γ-globin gene promoter at the position -175 (T-C) in erythroid progenitor cell line (HUDEP-2) and in adult hematopoietic stem cells (HSCs) to induced therapeutic levels of fetal globin in differentiated erythroid cells. This invention can be used to manipulate the HSCs from sickle cell disease or β-thalassemia patients to induce fetal hemoglobin which ameliorates the disease severity.


human γ-globin gene promoter, position -175 (T-C), erythroid progenitor cell line (HUDEP-2), hematopoietic stem cells (HSCs), fetal globin, differentiated erythroid cell, sickle cell disease, β-thalassemia.

Granted patents or published applications

Pending US patent.

Related scientific references

Mayuranathan, T., Newby, G.A., Feng, R. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet 55, 1210–1220 (2023).

Licensing opportunities

We are seeking a partner to develop this technology

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.